Publication Information

{'id': 'https://openalex.org/W4393095897', 'doi': 'https://doi.org/10.1158/1538-7445.am2024-1964', 'title': 'Abstract 1964: Furmonertinib is a brain-penetrant EGFR TKI highly active in uncommon EGFR mutations, including PACC and exon 20 insertions', 'display_name': 'Abstract 1964: Furmonertinib is a brain-penetrant EGFR TKI highly active in uncommon EGFR mutations, including PACC and exon 20 insertions', 'publication_year': 2024, 'publication_date': '2024-03-22', 'ids': {'openalex': 'https://openalex.org/W4393095897', 'doi': 'https://doi.org/10.1158/1538-7445.am2024-1964'}, 'language': 'en', 'primary_location': {'is_oa': False, 'landing_page_url': 'https://doi.org/10.1158/1538-7445.am2024-1964', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S168522863', 'display_name': 'Cancer Research', 'issn_l': '0008-5472', 'issn': ['0008-5472', '1538-7445'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310320273', 'host_organization_name': 'American Association for Cancer Research', 'host_organization_lineage': ['https://openalex.org/P4310320273'], 'host_organization_lineage_names': ['American Association for Cancer Research'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}, 'type': 'article', 'type_crossref': 'journal-article', 'indexed_in': ['crossref'], 'open_access': {'is_oa': False, 'oa_status': 'closed', 'oa_url': None, 'any_repository_has_fulltext': False}, 'authorships': [{'author_position': 'first', 'author': {'id': 'https://openalex.org/A5040693824', 'display_name': 'Monique B. Nilsson', 'orcid': 'https://orcid.org/0000-0002-0975-8833'}, 'institutions': [{'id': 'https://openalex.org/I1343551460', 'display_name': 'The University of Texas MD Anderson Cancer Center', 'ror': 'https://ror.org/04twxam07', 'country_code': 'US', 'type': 'healthcare', 'lineage': ['https://openalex.org/I1343551460']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Monique B. Nilsson', 'raw_affiliation_strings': ['1The University of Texas MD Anderson Cancer Center, Houston, TX;'], 'affiliations': [{'raw_affiliation_string': '1The University of Texas MD Anderson Cancer Center, Houston, TX;', 'institution_ids': ['https://openalex.org/I1343551460']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5029803492', 'display_name': 'Zineb Mounir', 'orcid': None}, 'institutions': [], 'countries': [], 'is_corresponding': False, 'raw_author_name': 'Zineb Mounir', 'raw_affiliation_strings': ['2ArriVent Biopharma, Inc., Burlingame, CA;'], 'affiliations': [{'raw_affiliation_string': '2ArriVent Biopharma, Inc., Burlingame, CA;', 'institution_ids': []}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5022619396', 'display_name': 'Luna Musib', 'orcid': 'https://orcid.org/0000-0002-6476-7919'}, 'institutions': [], 'countries': [], 'is_corresponding': False, 'raw_author_name': 'Luna Musib', 'raw_affiliation_strings': ['2ArriVent Biopharma, Inc., Burlingame, CA;'], 'affiliations': [{'raw_affiliation_string': '2ArriVent Biopharma, Inc., Burlingame, CA;', 'institution_ids': []}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5113673162', 'display_name': 'Junqin He', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I1343551460', 'display_name': 'The University of Texas MD Anderson Cancer Center', 'ror': 'https://ror.org/04twxam07', 'country_code': 'US', 'type': 'healthcare', 'lineage': ['https://openalex.org/I1343551460']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Junqin He', 'raw_affiliation_strings': ['1The University of Texas MD Anderson Cancer Center, Houston, TX;'], 'affiliations': [{'raw_affiliation_string': '1The University of Texas MD Anderson Cancer Center, Houston, TX;', 'institution_ids': ['https://openalex.org/I1343551460']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5058694333', 'display_name': 'Xiaoxing Yu', 'orcid': 'https://orcid.org/0000-0002-1607-0973'}, 'institutions': [{'id': 'https://openalex.org/I1343551460', 'display_name': 'The University of Texas MD Anderson Cancer Center', 'ror': 'https://ror.org/04twxam07', 'country_code': 'US', 'type': 'healthcare', 'lineage': ['https://openalex.org/I1343551460']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Xiaoxing Yu', 'raw_affiliation_strings': ['1The University of Texas MD Anderson Cancer Center, Houston, TX;'], 'affiliations': [{'raw_affiliation_string': '1The University of Texas MD Anderson Cancer Center, Houston, TX;', 'institution_ids': ['https://openalex.org/I1343551460']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5100404173', 'display_name': 'Qing Li', 'orcid': 'https://orcid.org/0000-0003-3087-4692'}, 'institutions': [], 'countries': ['CN'], 'is_corresponding': False, 'raw_author_name': 'Qing Li', 'raw_affiliation_strings': ['3Allist Pharmaceuticals Co., Ltd., Shanghai, China.'], 'affiliations': [{'raw_affiliation_string': '3Allist Pharmaceuticals Co., Ltd., Shanghai, China.', 'institution_ids': []}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5004078675', 'display_name': 'Huibing Luo', 'orcid': None}, 'institutions': [], 'countries': ['CN'], 'is_corresponding': False, 'raw_author_name': 'Huibing Luo', 'raw_affiliation_strings': ['3Allist Pharmaceuticals Co., Ltd., Shanghai, China.'], 'affiliations': [{'raw_affiliation_string': '3Allist Pharmaceuticals Co., Ltd., Shanghai, China.', 'institution_ids': []}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5048380048', 'display_name': 'John V. Heymach', 'orcid': 'https://orcid.org/0000-0001-9068-8942'}, 'institutions': [{'id': 'https://openalex.org/I1343551460', 'display_name': 'The University of Texas MD Anderson Cancer Center', 'ror': 'https://ror.org/04twxam07', 'country_code': 'US', 'type': 'healthcare', 'lineage': ['https://openalex.org/I1343551460']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'John V. Heymach', 'raw_affiliation_strings': ['1The University of Texas MD Anderson Cancer Center, Houston, TX;'], 'affiliations': [{'raw_affiliation_string': '1The University of Texas MD Anderson Cancer Center, Houston, TX;', 'institution_ids': ['https://openalex.org/I1343551460']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5030505864', 'display_name': 'Jerry Y. Hsu', 'orcid': 'https://orcid.org/0000-0002-0365-7214'}, 'institutions': [], 'countries': [], 'is_corresponding': False, 'raw_author_name': 'Jerry Y. Hsu', 'raw_affiliation_strings': ['2ArriVent Biopharma, Inc., Burlingame, CA;'], 'affiliations': [{'raw_affiliation_string': '2ArriVent Biopharma, Inc., Burlingame, CA;', 'institution_ids': []}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5055658805', 'display_name': 'Stuart Lutzker', 'orcid': None}, 'institutions': [], 'countries': [], 'is_corresponding': False, 'raw_author_name': 'Stuart Lutzker', 'raw_affiliation_strings': ['2ArriVent Biopharma, Inc., Burlingame, CA;'], 'affiliations': [{'raw_affiliation_string': '2ArriVent Biopharma, Inc., Burlingame, CA;', 'institution_ids': []}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5007462622', 'display_name': 'Xiuning Le', 'orcid': 'https://orcid.org/0000-0002-8554-1185'}, 'institutions': [{'id': 'https://openalex.org/I1343551460', 'display_name': 'The University of Texas MD Anderson Cancer Center', 'ror': 'https://ror.org/04twxam07', 'country_code': 'US', 'type': 'healthcare', 'lineage': ['https://openalex.org/I1343551460']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Xiuning Le', 'raw_affiliation_strings': ['1The University of Texas MD Anderson Cancer Center, Houston, TX;'], 'affiliations': [{'raw_affiliation_string': '1The University of Texas MD Anderson Cancer Center, Houston, TX;', 'institution_ids': ['https://openalex.org/I1343551460']}]}, {'author_position': 'last', 'author': {'id': 'https://openalex.org/A5001204975', 'display_name': 'Marcin Kowanetz', 'orcid': None}, 'institutions': [], 'countries': [], 'is_corresponding': False, 'raw_author_name': 'Marcin Kowanetz', 'raw_affiliation_strings': ['2ArriVent Biopharma, Inc., Burlingame, CA;'], 'affiliations': [{'raw_affiliation_string': '2ArriVent Biopharma, Inc., Burlingame, CA;', 'institution_ids': []}]}], 'institution_assertions': [], 'countries_distinct_count': 2, 'institutions_distinct_count': 1, 'corresponding_author_ids': [], 'corresponding_institution_ids': [], 'apc_list': None, 'apc_paid': None, 'fwci': 0.0, 'has_fulltext': False, 'cited_by_count': 0, 'citation_normalized_percentile': {'value': 0.0, 'is_in_top_1_percent': False, 'is_in_top_10_percent': False}, 'cited_by_percentile_year': {'min': 0, 'max': 84}, 'biblio': {'volume': '84', 'issue': '6_Supplement', 'first_page': '1964', 'last_page': '1964'}, 'is_retracted': False, 'is_paratext': False, 'primary_topic': {'id': 'https://openalex.org/T10417', 'display_name': 'Lung Cancer Treatments and Mutations', 'score': 0.9926, 'subfield': {'id': 'https://openalex.org/subfields/2740', 'display_name': 'Pulmonary and Respiratory Medicine'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, 'topics': [{'id': 'https://openalex.org/T10417', 'display_name': 'Lung Cancer Treatments and Mutations', 'score': 0.9926, 'subfield': {'id': 'https://openalex.org/subfields/2740', 'display_name': 'Pulmonary and Respiratory Medicine'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T10755', 'display_name': 'HER2/EGFR in Cancer Research', 'score': 0.9524, 'subfield': {'id': 'https://openalex.org/subfields/2730', 'display_name': 'Oncology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T11067', 'display_name': 'Colorectal Cancer Treatments and Studies', 'score': 0.9159, 'subfield': {'id': 'https://openalex.org/subfields/2730', 'display_name': 'Oncology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}], 'keywords': [{'id': 'https://openalex.org/keywords/penetrant', 'display_name': 'Penetrant (biochemical)', 'score': 0.59723216}], 'concepts': [{'id': 'https://openalex.org/C36823959', 'wikidata': 'https://www.wikidata.org/wiki/Q373027', 'display_name': 'Exon', 'level': 3, 'score': 0.7002184}, {'id': 'https://openalex.org/C2779335537', 'wikidata': 'https://www.wikidata.org/wiki/Q7162617', 'display_name': 'Penetrant (biochemical)', 'level': 2, 'score': 0.59723216}, {'id': 'https://openalex.org/C71924100', 'wikidata': 'https://www.wikidata.org/wiki/Q11190', 'display_name': 'Medicine', 'level': 0, 'score': 0.43597093}, {'id': 'https://openalex.org/C502942594', 'wikidata': 'https://www.wikidata.org/wiki/Q3421914', 'display_name': 'Cancer research', 'level': 1, 'score': 0.42699486}, {'id': 'https://openalex.org/C86803240', 'wikidata': 'https://www.wikidata.org/wiki/Q420', 'display_name': 'Biology', 'level': 0, 'score': 0.3700511}, {'id': 'https://openalex.org/C54355233', 'wikidata': 'https://www.wikidata.org/wiki/Q7162', 'display_name': 'Genetics', 'level': 1, 'score': 0.33100867}, {'id': 'https://openalex.org/C104317684', 'wikidata': 'https://www.wikidata.org/wiki/Q7187', 'display_name': 'Gene', 'level': 2, 'score': 0.25210002}, {'id': 'https://openalex.org/C150903083', 'wikidata': 'https://www.wikidata.org/wiki/Q7108', 'display_name': 'Biotechnology', 'level': 1, 'score': 0.060796916}], 'mesh': [], 'locations_count': 1, 'locations': [{'is_oa': False, 'landing_page_url': 'https://doi.org/10.1158/1538-7445.am2024-1964', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S168522863', 'display_name': 'Cancer Research', 'issn_l': '0008-5472', 'issn': ['0008-5472', '1538-7445'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310320273', 'host_organization_name': 'American Association for Cancer Research', 'host_organization_lineage': ['https://openalex.org/P4310320273'], 'host_organization_lineage_names': ['American Association for Cancer Research'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}], 'best_oa_location': None, 'sustainable_development_goals': [{'score': 0.74, 'display_name': 'Good health and well-being', 'id': 'https://metadata.un.org/sdg/3'}], 'grants': [], 'datasets': [], 'versions': [], 'referenced_works_count': 0, 'referenced_works': [], 'related_works': ['https://openalex.org/W4238561802', 'https://openalex.org/W2130076355', 'https://openalex.org/W2119695867', 'https://openalex.org/W2082860237', 'https://openalex.org/W2073909843', 'https://openalex.org/W2017300733', 'https://openalex.org/W1993764875', 'https://openalex.org/W1990804418', 'https://openalex.org/W1965484690', 'https://openalex.org/W1593037043'], 'abstract_inverted_index': {'Abstract': [0], 'Background:': [1], 'Furmonertinib': [2, 485], '(AST2818,': [3], 'furmo)': [4], 'is': [5, 52, 336, 366, 427, 446, 486], 'an': [6], 'oral,': [7], 'highly': [8, 285, 491], 'brain-penetrant,': [9], 'and': [10, 19, 30, 72, 83, 117, 148, 153, 160, 167, 187, 216, 229, 255, 296, 310, 317, 345, 363, 374, 382, 408, 410, 419, 425, 434, 499], 'broadly': [11, 340], 'active': [12, 341, 429, 492], 'mutation-selective': [13], 'EGFR': [14, 21, 41, 93, 124, 220, 234, 257, 274, 442, 489, 495], 'inhibitor': [15], 'against': [16, 313, 396, 431], 'both': [17, 343, 432], 'classical': [18, 219, 256], 'uncommon': [20, 92, 494], 'mutations': [22], '(mts).': [23], 'Furmo': [24, 51], 'has': [25, 73], 'demonstrated': [26], 'promising': [27, 309], 'interim': [28], 'efficacy': [29, 193], 'safety': [31], 'in': [32, 56, 68, 78, 104, 146, 158, 180, 196, 222, 276, 384, 394, 400, 423, 441, 450, 493], 'non-small': [33], 'cell': [34, 182, 279], 'lung': [35], 'cancer': [36, 144, 270, 421], '(NSCLC)': [37], 'patients': [38], '(pts)': [39], 'with': [40, 66, 130, 253, 361, 371], 'exon': [42, 500], '20': [43, 501], 'insertion': [44], '(ex20ins)': [45], 'mts': [46, 87, 94, 132, 142, 221, 258, 266, 275, 283, 365, 416], '(Han': [47], 'et': [48, 96], 'al.,': [49, 97], '2023).': [50], 'currently': [53, 447], 'being': [54, 448], 'studied': [55], 'a': [57, 249, 268, 451, 487], 'global': [58, 452], 'Phase': [59], '3': [60], 'trial': [61], 'for': [62, 128, 172, 184, 214, 218, 327, 510], '1st': [63], 'line': [64], 'pts': [65, 129], 'ex20ins': [67, 103, 161, 189, 215, 231, 254, 332, 346, 362, 435], 'NSCLC': [69, 147, 424, 445], '(FURVENT;': [70], 'NCT05607550)': [71], 'received': [74], 'FDA': [75], 'Breakthrough': [76], 'Designation': [77], 'this': [79, 136], 'pt': [80, 348], 'population.': [81], 'P-loop': [82], 'αC-helix': [84], 'Compressing': [85], '(PACC)': [86], 'represent': [88], 'another': [89], 'subset': [90], 'of': [91, 156, 232, 264, 439, 506], '(Robichaux': [95], '2021)': [98], 'that': [99, 239, 358], 'are': [100, 118, 402, 417], 'similar': [101, 250, 269, 297, 326], 'to': [102, 226, 248, 287, 299, 331, 338, 377, 404], 'narrowing': [105], 'the': [106, 150, 262, 303, 385, 507], 'drug': [107, 353, 386], 'binding': [108, 154, 387], 'pocket;': [109], 'include': [110], 'e.g.': [111], 'G719X,': [112], 'S768I,': [113], 'E709X,': [114], 'L747X,': [115], 'V774M;': [116], 'found': [119], 'as': [120, 143, 243, 252, 267, 272, 329], 'single': [121, 314], 'or': [122], 'compound': [123, 318], 'mts.': [125, 162, 190, 235, 322, 333, 436], 'Treatment': [126], 'options': [127], 'PACC': [131, 141, 159, 186, 208, 228, 247, 265, 282, 321, 328, 344, 364, 397, 415, 433, 443, 498], 'remain': [133], 'limited.': [134], 'In': [135, 175, 191], 'study,': [137], 'we': [138], 'further': [139, 260, 390], 'characterized': [140], 'drivers': [145, 422], 'evaluated': [149, 449], 'pre-clinical': [151], 'activity': [152, 298, 312, 438], 'mechanisms': [155], 'furmo': [157, 288, 307, 335, 392, 426, 440], 'Methods:': [163], 'AACR': [164], 'Project': [165], 'GENIE': [166], 'TEMPUS': [168], 'databases': [169], 'were': [170, 284, 325], 'used': [171], 'mutation': [173], 'analysis.': [174], 'vitro': [176], 'potency': [177, 293], 'was': [178, 194, 202, 210], 'determined': [179], 'Ba/F3': [181, 278], 'lines': [183, 280], '33': [185], '16': [188], 'vivo': [192, 395], 'conducted': [195], 'pt-derived': [197], 'xenografts': [198], '(PDXs).': [199], 'Molecular': [200, 355], 'modeling': [201], 'performed': [203], 'using': [204], 'MOE': [205], 'software.': [206], 'Results:': [207], 'prevalence': [209], '2.4%': [211], 'vs.': [212, 294], '1.6%': [213], '14%': [217], 'all': [223, 233], 'NSCLC,': [224], 'corresponding': [225], '10.4%': [227], '7%': [230], 'Co-mutation': [236], 'analysis': [237], 'revealed': [238, 357], 'other': [240, 273], 'oncogenes,': [241], 'such': [242], 'p53,': [244], 'co-occurred': [245], 'alongside': [246], 'rate': [251], 'which': [259, 289], 'supports': [261], 'role': [263], 'driver': [271], 'NSCLC.': [277], 'harboring': [281], 'sensitive': [286], 'showed': [290, 308], 'overall': [291], 'superior': [292], 'osimertinib': [295], 'afatinib.': [300], 'When': [301], 'comparing': [302], 'mutant/wild-type': [304], 'IC50': [305, 323], 'ratio,': [306], 'high': [311], '(e.g.': [315, 319], 'G719X)': [316], 'ex19del+L718V)': [320], 'values': [324], 'compared': [330], 'Therefore,': [334], 'predicted': [337], 'be': [339, 412], 'across': [342], 'mutant': [347, 444], 'populations': [349], 'at': [350], 'clinically': [351], 'achievable': [352], 'levels.': [354], 'modelling': [356], 'furmo’s': [359], 'interaction': [360], 'stabilized': [367], 'through': [368], 'hydrogen': [369], 'bonds': [370], 'specific': [372], 'sites': [373], 'its': [375], 'proximity': [376], 'hydrophobic': [378], 'residues': [379], 'including': [380, 497], 'L792': [381], 'P794': [383], 'pocket.': [388], 'To': [389], 'characterize': [391], 'sensitivity': [393], 'mts,': [398], 'studies': [399], 'PDXs': [401], 'ongoing': [403], 'evaluate': [405], 'efficacy,': [406], 'pharmacokinetics': [407], 'pharmacodynamics': [409], 'will': [411], 'presented.': [413], 'Conclusions:': [414], 'important': [418], 'prevalent': [420], 'similarly': [428], 'preclinically': [430], 'The': [437], 'study': [453], 'FURTHER': [454], '(NCT05364073).': [455], 'Citation': [456], 'Format:': [457], 'Monique': [458], 'B.': [459], 'Nilsson,': [460], 'Zineb': [461], 'Mounir,': [462], 'Luna': [463], 'Musib,': [464], 'Junqin': [465], 'He,': [466], 'Xiaoxing': [467], 'Yu,': [468], 'Qing': [469], 'Li,': [470], 'Huibing': [471], 'Luo,': [472], 'John': [473], 'V.': [474], 'Heymach,': [475], 'Jerry': [476], 'Y.': [477], 'Hsu,': [478], 'Stuart': [479], 'Lutzker,': [480], 'Xiuning': [481], 'Le,': [482], 'Marcin': [483], 'Kowanetz.': [484], 'brain-penetrant': [488], 'TKI': [490], 'mutations,': [496], 'insertions': [502], '[abstract].': [503], 'In:': [504], 'Proceedings': [505], 'American': [508], 'Association': [509], 'Cancer': [511, 529], 'Research': [512], 'Annual': [513], 'Meeting': [514], '2024;': [515], 'Part': [516], '1': [517], '(Regular': [518], 'Abstracts);': [519], '2024': [520], 'Apr': [521], '5-10;': [522], 'San': [523], 'Diego,': [524], 'CA.': [525], 'Philadelphia': [526], '(PA):': [527], 'AACR;': [528], 'Res': [530], '2024;84(6_Suppl):Abstract': [531], 'nr': [532], '1964.': [533]}, 'cited_by_api_url': 'https://api.openalex.org/works?filter=cites:W4393095897', 'counts_by_year': [], 'updated_date': '2024-12-15T13:36:55.310409', 'created_date': '2024-03-23'}